FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094544181> ?p ?o ?g. }

• W2094544181 endingPage "176" @default.
• W2094544181 startingPage "171" @default.
• W2094544181 abstract "To assess the efficacy and safety of vildagliptin versus other oral glucose-lowering drugs added to antidiabetic monotherapy in Belgian patients with type 2 diabetes mellitus, in comparison to the global EDGE study results.This is a pre-specified post-hoc subanalysis of the Belgian patient cohort from a worldwide 1-year observational study that compared the effectiveness and tolerability of vildagliptin to other oral antidiabetic agents in type 2 diabetes patients failing monotherapy with oral glucose-lowering agents (EDGE). A total of 1793 Belgian patients were enrolled. Physicians could add any oral antidiabetic drug and patients entered either into the vildagliptin or the comparator cohort. The primary effectiveness and tolerability endpoint was defined as the proportion of patients having a treatment response (HbA1c reduction from baseline to month 12 endpoint >0·3%) without hypoglycemia, weight gain, peripheral oedema, or gastrointestinal side-effects.In the Belgian population, 37·8% of patients in the vildagliptin group and 32·8% in the comparator group had a decrease in HbA1c of >0·3% without the predefined tolerability issues of hypoglycemia, weight gain, oedema or, gastrointestinal complaints (primary endpoint), resulting in an unadjusted odds ratio of 1·24 (95% CI: 0·96-1·61). Mean HbA1c change from baseline was -0·81% in the vildagliptin cohort and -0·75% in the comparator cohort. Overall, vildagliptin was well tolerated with similarly low incidences of total adverse events (14·9% versus 14·5% in the compactor group) and serious adverse events (2·7% versus 2·5% in the comparator group).In this EDGE subgroup of Belgian patients with type 2 diabetes who do not achieve the glycemic targets with monotherapy, a similar trend as in the global EDGE study was observed. Adding vildagliptin as a second oral glucose-lowering agent resulted in lowering HbA1c to <7% without weight gain, hypoglycemia or peripheral oedema in a higher proportion of patients than comparator oral antidiabetic drugs, with no differences in the reported number of adverse events." @default.
• W2094544181 created "2016-06-24" @default.
• W2094544181 creator A5006089930 @default.
• W2094544181 creator A5053469409 @default.
• W2094544181 creator A5087589975 @default.
• W2094544181 date "2014-03-20" @default.
• W2094544181 modified "2023-10-14" @default.
• W2094544181 title "Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE):post-hocsubanalysis of the Belgian data" @default.
• W2094544181 cites W1991951001 @default.
• W2094544181 cites W2019105043 @default.
• W2094544181 cites W2027249582 @default.
• W2094544181 cites W2060083804 @default.
• W2094544181 cites W2103828712 @default.
• W2094544181 cites W2124465362 @default.
• W2094544181 cites W2172193326 @default.
• W2094544181 cites W2188846692 @default.
• W2094544181 doi "https://doi.org/10.1179/2295333714y.0000000018" @default.
• W2094544181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24820924" @default.
• W2094544181 hasPublicationYear "2014" @default.
• W2094544181 type Work @default.
• W2094544181 sameAs 2094544181 @default.
• W2094544181 citedByCount "3" @default.
• W2094544181 countsByYear W20945441812015 @default.
• W2094544181 countsByYear W20945441812016 @default.
• W2094544181 countsByYear W20945441812019 @default.
• W2094544181 crossrefType "journal-article" @default.
• W2094544181 hasAuthorship W2094544181A5006089930 @default.
• W2094544181 hasAuthorship W2094544181A5053469409 @default.
• W2094544181 hasAuthorship W2094544181A5087589975 @default.
• W2094544181 hasConcept C126322002 @default.
• W2094544181 hasConcept C134018914 @default.
• W2094544181 hasConcept C168563851 @default.
• W2094544181 hasConcept C197934379 @default.
• W2094544181 hasConcept C203092338 @default.
• W2094544181 hasConcept C2776453732 @default.
• W2094544181 hasConcept C2777180221 @default.
• W2094544181 hasConcept C2778375690 @default.
• W2094544181 hasConcept C2779306644 @default.
• W2094544181 hasConcept C2780668416 @default.
• W2094544181 hasConcept C2908647359 @default.
• W2094544181 hasConcept C555293320 @default.
• W2094544181 hasConcept C71924100 @default.
• W2094544181 hasConcept C72563966 @default.
• W2094544181 hasConcept C99454951 @default.
• W2094544181 hasConceptScore W2094544181C126322002 @default.
• W2094544181 hasConceptScore W2094544181C134018914 @default.
• W2094544181 hasConceptScore W2094544181C168563851 @default.
• W2094544181 hasConceptScore W2094544181C197934379 @default.
• W2094544181 hasConceptScore W2094544181C203092338 @default.
• W2094544181 hasConceptScore W2094544181C2776453732 @default.
• W2094544181 hasConceptScore W2094544181C2777180221 @default.
• W2094544181 hasConceptScore W2094544181C2778375690 @default.
• W2094544181 hasConceptScore W2094544181C2779306644 @default.
• W2094544181 hasConceptScore W2094544181C2780668416 @default.
• W2094544181 hasConceptScore W2094544181C2908647359 @default.
• W2094544181 hasConceptScore W2094544181C555293320 @default.
• W2094544181 hasConceptScore W2094544181C71924100 @default.
• W2094544181 hasConceptScore W2094544181C72563966 @default.
• W2094544181 hasConceptScore W2094544181C99454951 @default.
• W2094544181 hasIssue "3" @default.
• W2094544181 hasLocation W20945441811 @default.
• W2094544181 hasLocation W20945441812 @default.
• W2094544181 hasOpenAccess W2094544181 @default.
• W2094544181 hasPrimaryLocation W20945441811 @default.
• W2094544181 hasRelatedWork W1986053789 @default.
• W2094544181 hasRelatedWork W2055753691 @default.
• W2094544181 hasRelatedWork W2062321935 @default.
• W2094544181 hasRelatedWork W2099305220 @default.
• W2094544181 hasRelatedWork W2099677425 @default.
• W2094544181 hasRelatedWork W2117762041 @default.
• W2094544181 hasRelatedWork W2124465362 @default.
• W2094544181 hasRelatedWork W2335096023 @default.
• W2094544181 hasRelatedWork W3135879765 @default.
• W2094544181 hasRelatedWork W4220781513 @default.
• W2094544181 hasVolume "69" @default.
• W2094544181 isParatext "false" @default.
• W2094544181 isRetracted "false" @default.
• W2094544181 magId "2094544181" @default.
• W2094544181 workType "article" @default.